Media store

Media Releases

Published on: 30 September 2019

Roche presents positive Phase III results for Tecentriq® (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer

Roche today presented positive results from the Phase III IMvigor130 study evaluating Tecentriq® (atezolizumab) plus platinum-based chemotherapy versus chemotherapy alone for the first-line (initial) ...

Published on: 30 September 2019

Roche to present results of first prospective trial using blood-based next generation sequencing which successfully identifies people for treatment with Alecensa

Roche will today announce positive results from a single-arm cohort of the Phase II/III Blood First Assay Screening Trial (BFAST), the first prospective study to use only blood-based next generation ...

Published on: 30 September 2019

FDA approves Roche’s Rituxan (rituximab) in children with two rare blood vessel disorders

Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Rituxan® (rituximab), in combination with glucocorticoids, for the treatment of granulomatosis with polyangiitis ...

Upcoming Events

All

16October

Third quarter sales 2019

(GMT)

Basel

17March

Annual General Meeting (tentative)

(CEST)

Basel, Switzerland

add to calendar

22April

First quarter sales 2020

(CEST)

Basel

23July

Half year results 2020

(CEST)

Basel

Topics

Media contacts

For media requests

+41 61 688 8888

Media Relations Team

For all general enquiries

Please call the Roche switchboard on
Phone:+41 61 688 11 11